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Abstract 
Introduction: Longitudinal bone growth ceases by the end of puberty, and it is thought to be a result, in both sexes, of increased pubertal 
oestrogen serum concentrations. Since peak bone mass is achieved by the third decade of life or later, the aim of this study was to relate sex 
steroid hormones and sex hormone binding globulin (SHBG) levels to bone quality in men during their third and fourth decades of life.
Material and methods: Eighty men, healthy volunteers aged between 18 and 39 years, were subjected to an interviewer-administered 
questionnaire, body mass index (BMI) measurement, blood sample and calcaneal quantitative ultrasound (QUS) (Hologic-SAHARA). Blood 
was assessed for testosterone (T), oestradiol (E2), dehydroepiandrosterone sulfate (DHEAS), SHBG, luteinising hormone (LH) and follicle 
stimulating hormone (FSH). Free and bioavailable T and E2 levels were calculated knowing SHBG and albumin levels. 
Results: While T, E2, DHEAS, LH and FSH levels were not related, free and bioavailable fractions of T and E2 were positively associated 
with QUS readings. SHBG level was associated negatively. After dichotomisation for age, the associations remained significant only for 
younger subjects (18–30 years, n = 47). After adjustment for other co-variants, only SHBG in younger subjects retained its negative associa-
tion with QUS. Older subjects (31–39 years, n = 33) revealed higher BMI and lower serum concentrations of total (–17 %), free (–18.5%) 
and bioavailable (–22.5%) levels of E2 than younger subjects. 
Conclusion: Free and bioavailable fractions of sex steroids may influence bones in young men, depending on age and E2 level. 
(Endokrynol Pol 2014; 65 (5): 357–364)
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Streszczenie 
Wstęp: Wzrost kości na długość ustaje wraz z końcem dojrzewania płciowego i wykazano, że u obu płci jest to wynik wzrostu stężenia 
estrogenów we krwi. Skoro przyjęto, że szczytowa masa kostna jest osiągana dopiero w trzeciej dekadzie życia lub po trzydziestce, 
badano związki pomiędzy stężeniami steroidów płciowych i białka wiążącego steroidy płciowe (SHBG) a jakością kości u mężczyzn 
w trzeciej i czwartej dekadzie życia. 
Materiał i metody: Osiemdziesięciu mężczyzn, zdrowych ochotników w wieku 18–39 lat wypełniło kwestionariusz z wywiadem, zmie-
rzono u nich wskaźnik masy ciała (BMI) i wykonano ilościową analizę ultrasonograficzną kości piętowej (QUS) (Hologic-SAHARA). We 
krwi oznaczono stężenia testosteronu (T), estradiolu (E2), siarczanu dehydroepiandrosteronu (DHEAS), SHBG, hormonu luteinizującego 
(LH) i hormonu folikulotropowego (FSH). Znając stężenia SHBG i albumin, wyliczano stężenia wolnego i biodostępnego T i E2. 
Wyniki: Podczas gdy stężenia T, E2, DHEAS, LH i FSH nie wykazywały powiązań, stężenia wolnych i biodostępnych frakcji T i E2 były 
dodatnio związane z parametrami QUS. Stężenie SHBG wykazywało związek ujemny. Relacje te zależały od wieku. Mianowicie, po 
podziale na dwie grupy wiekowe, relacje pozostały znamienne tylko wśród młodszych mężczyzn (18–30 lat, n = 47). Analiza wieloczyn-
nikowa wykazała, że tylko stężenie SHBG u młodszych mężczyzn zachowało znamiennie ujemny związek ze stanem kości. Starsi (31–39 
lat, n = 33) wykazali wyższy BMI, a niższe stężenie całkowitego (–17%), wolnego (–18,5%) i biodostępnego (–22,55%) E2 w porównaniu 
z młodszymi badanymi. 
Wnioski: Wolne i biodostępne frakcje steroidów płciowych mogą wpływać na kości u młodych mężczyzn, w zależności od wieku i stężenia 
E2. (Endokrynol Pol 2014; 65 (5): 357–364)
Słowa kluczowe: testosteron; estradiol; SHBG; kości; ultrasonografia
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Study questionnaires and clinical data 
The postal questionnaire included questions concern-
ing current smoking and alcohol consumption in the 
previous year (response set = every day/5–6 days per 
week/3–4 days per week/1–2 days per week/less than 
once a week/not at all). The main study questionnaire 
included general health, physical activity, assessed as 
frequency and duration of walking. Frequency per 
week was categorised as 1) none, 2) seldom, 3) from 
time to time or 4) frequent. Duration of walking per 
day was categorised as 1) less than 1 hour, 2) about 
1 hour but less than 2 h, 3) 2–4 hours, or 4) more than 
4 hours. Height and weight were measured in a stand-
ardised fashion. Body weight was measured to the 
nearest 0.1kg using an electronic scale (SECA, model 
no. 8801321009, SECA UK Ltd) and height to the nearest 
1mm using a stadiometer (Leicester Height Measure, 
SECA UK Ltd). Body mass index was calculated (BMI 
= weight/height2).
Hormone measurements
After a single fasting morning (before 10am), a venous 
blood sample was obtained from all subjects. The 
serum was separated immediately after phlebotomy 
and stored at –80°C until single run assays. Determi-
nations of T, E2, DHEAS, SHBG were performed using 
chemiluminescence immunoassay (Immulite 1000, 
DPC, USA). Detection limits were 0.5 nmol/L for T, 
55 pmol/L for E2, 0.081 μmol/L for DHEAS, and 0.2 
nmol/L for SHBG. The coefficients of variation within 
runs were 13% for T, 15% for E2, 13% for DHEAS and 
6.9% for SHBG. FSH and LH concentrations were 
determined by an immunometric technique (Vit-
ros System, Ortho-Clinical Diagnostics, USA) with 
a sensitivity of 0.5 mIU/mL for both, and with an intra-
assay precision of 2.2% (FSH) and 2.6% (LH). The free 
and bio-available T and E2 levels were derived from 
total hormone, SHBG and albumin concentrations 
using mass action equations and association constants 
of Vermeulen et al. [1] and Van Pottelbergh et al. [14].
QUS of the heel
QUS of the left heel was performed with the Sahara 
Clinical Sonometer (Hologic, Bedford, MA, USA) using 
a standardised protocol. Outputs included the rate of 
loss of ultrasonic intensity with frequency (broadband 
ultrasound attenuation [BUA] measured in dB/MHz 
using a Fourier transformation of the recorded signal) 
and the velocity of ultrasound transmission through 
bone (speed of sound [SOS] measured in m/s from the 
sound propagation time between the transducers). 
In addition, the quantitative ultrasound index (QUI), 
a measure of stiffness, was derived from the BUA and 
SOS measures: QUI = 0.41 (SOS) + 0.41 (BUA) – 571. 
Introduction
Testosterone (T) and oestradiol (E2) are the two most 
important sex steroids in men and women respectively. 
In the circulation they are bound or unbound to serum 
proteins. Their serum protein-bound fractions are bio-
logically inactive. The bioactive fractions of circulating 
hormones are either free (non-bound to sex hormone 
binding protein, SHBG, and albumin) or bioavailable 
(non-bound to SHBG) [1]. Studies on individuals with 
androgen insensitivity support the role of T in maintain-
ing trabecular bone [2], and androgen receptors have 
been reported in human osteoblasts [3]. However, in 
a large cohort of middle-aged and elderly men, total and 
free E2, but not T, blood levels were found to positively 
correlate with bone health as estimated by quantitative 
ultrasonography (QUS) at the calcaneus [4]. 
Longitudinal bone growth ceases by the end of pu-
berty and it is thought to be a result, in both males and 
females, of the actions of increased pubertal oestrogen 
concentrations to induce epiphyseal maturation and 
closure [5–8]. However, bone development progresses 
beyond puberty and it is believed that peak bone mass, 
a significant predictor of osteoporosis, is achieved by the 
early- to mid-20 s or after 30 years of age [9–12]. In the 
present study, we investigated the association between 
serum concentrations of sex steroids, SHBG, luteinis-
ing hormone (LH) and follicle stimulating hormone 
(FSH), the pituitary hormones that control gonadal 
function, and the bone status of men in the age-span 
of 18–39 years.
Material and methods
Subjects
The study was performed in the outpatient clinic of 
the University Hospital at Medical University of Łódź, 
Poland. The study protocol was approved by the 
Ethical Committee of the Medical University in Łódź 
(RNN/145/05/KE) and informed consent was obtained 
from all participants. A group of 300 men was randomly 
recruited from a population-based sample of the Łódź 
city population register for participation in this study. 
The criterion was age between 18 and 39 years. Subjects 
were invited by letter to attend a screening visit at the 
Department of Andrology and Reproductive Endocri-
nology between March 2006 and June 2007. Eighty men 
agreed to participate, with an overall response rate for 
participation of 26.7%. The subjects were asked to com-
plete a postal questionnaire and attend an interviewer-
assisted questionnaire, which included questions about 
physical activity and lifestyle. Other data from these 
individuals including blood biochemistry data has 
previously been described [13]. 
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The short-term precision of the method was based on 
duplicate measurements performed in 20 randomly-
selected cohort members in the reference centre of the 
Department of Andrology and Endocrinology, Catholic 
University of Leuven (Prof. Dirk Van der Schueren). The 
in vivo coefficients of variation were 2.8% and 0.3% for 
BUA and SOS, respectively, and 2.3% for QUI.
Statistical analysis 
The data is expressed as mean ± standard deviation 
(SD) for parametric, or median (25–75% interval and 
range) for nonparametric, distributions. The distribu-
tion of data was assessed according to the Shapiro-Wilk 
test. One-way ANOVA was applied to assess the sta-
tistical significance for normally distributed data, while 
the Kruskal-Wallis or Mann-Whitney test was used for 
data which was not normally distributed. Differences 
were considered significant at p < 0.05. The associa-
tions between each of the ultrasound parameters and 
the different hormone levels were expressed as β coef-
ficients and 95% confidence intervals (CI). Analysis was 
performed using Statistica version 8.0.
Results
Eighty men aged from 18–39 years (mean age 28.2 years) 
were included in the analysis. All reported good general 
health and revealed a normal development of primary 
and secondary sexual characteristics. Of the subjects, 
33.7% reported that they currently smoke, 82.5% that 
they consume alcohol more than one day per week and 
58.7% reported physical activity. Subject characteristics 
are presented in Table I. Mean values for the hormones 
are shown in Table II. The level of T found in the entire 
group ranged between 8.2 and 27.7 nmol/L; the same 
for E2 was 45.5 and 208.8 pmol/L. 
Table III shows that while T, E2, DHEAS, LH or FSH 
levels were not related, the levels of free and bioavail-
able T, and E2 were significantly positively associated 
with QUS parameters, whereas SHBG level was associ-
ated negatively. 
When the subjects were divided by age, the as-
sociations remained significant for sex steroids in 
younger subjects (18–30 years, n = 47), but not in the 
older subgroup (31–39 years, n = 33) (Table IV). In the 
multivariate model including free and bio- available 
T, free and bio available E2, and SHBG as continuous 
variables, after adjustment for age, BMI, physical 
activity, current smoking and alcohol consump-
tion, only SHBG remained significantly associated 
with all QUS parameters among younger subjects 
(β = –1.0024, p = 0.037).
Older subjects (31–39 years) revealed significantly 
higher BMI and lower levels of total (–17%), free 
(–18.5%) and bio-available (–22.5%) E2 than the younger 
group. The total T, free T, SHBG, LH or FSH, BMI and 
QUS parameters were not found to be different be-
tween subgroups (Table V). There was no difference 
with respect to smoking habits, alcohol consumption or 
physical activity, and none of these factors influenced 
QUS (data not shown).
To further characterise the influence of age on hor-
mone levels, the subjects were stratified for 2-3 year age 
ranges as follows: 18-20 (n = 8), 21–23 (n = 16), 24–26 
(n = 11), 27–29 (n = 9), 30–32 (n = 17), 33–35 (n = 8), 
and 36–39 (n = 11). Significant changes concerned serum 
levels of BMI, free E2, bio-available E2 and SHBG. Figure 
1 demonstrates a stepwise increase of BMI between 
Table I. Subject characteristics
Tabela I. Charakterystyka grupy
Variable N = 80 
Mean (SD)
Age at interview (years) 28,2 (5,9)
Height [cm] 179.8 (4,6)
Weight [kg] 81.7 (13.4)
Body mass index [kg/m2] 25.2 (4.6)
Broadband ultrasound attenuation (BUA) 
(dB/MHz)
88.63 (18.4)
Speed of sound (m/s) (SOS) 1561.2 (38.5)
Quantitative ultrasound index (QUI) 104.9 (22.3)
%
Currently smoke (yes vs. no) 33.7
Alcohol consumption ≥ 1day/week 82.5
Physical activity (walking) (yes vs. no) 58.7
Table II. Hormone descriptives
Tabela II. Stężenia hormonów
Variable N = 80  
Mean (SD)
Reference 
range
Testosterone [nmol/L] 18.3 (5.2) 14.4–22.5
Free testosterone [pmol/L] 424.0 (129.7) 200–500
Bio-available testosterone [nmol/L] 10.8 (3.3)
Oestradiol [pmol/L] 113.5 (41.1) 88–142
Free oestradiol [pmol/L] 2.4 (0.9) 1.7–2.6
Bio-available oestradiol [pmol/L] 63.8 (24.9) 44–73
SHBG [nmol/L] 25.7 (10.6) 16–35
DHEAS [mmol/L] 7.2 (2.7) 2.2–13.9
LH [IU/L] 4.5 (1.8) 0.8–7.6
FSH [IU/L] 4.1 (2.2) 1.5–9.7
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Table III. Association between hormones or SHBG and QUS parameters in 80 men aged 18–39 years
Tabela III. Relacje pomiędzy stężeniami hormonów lub SHBG a parametrami QUS u 80 mężczyzn w wieku 18–39 lat
BUA (dB/Mhz) 
β-coefficient (95% CI)
SOS (m/s) 
β-coefficient (95% CI)
QUI 
β-coefficient (95% CI)
Testosterone [nmol/L] 0.059 (–0.738, 0.857) 0.624 (–1.035, 2.284)) 0.256 (–0.710, 1.223)
Free testosterone [pmol/L] 0.029 (–0.016, 0.061) 0,080 (0.015, 0.144)* 0.042 (0.005, 0.080)*
Bioavailable testosterone [nmol/L] 1.061 (–0.166, 2.289) 3.016 (0.494, 5.538)* 1.561 (0.084, 3.038)*
Oestradiol [pmol/L] 0.040 (–0.059, 0.141) 0.124 (–0.08, 0.333) 0.055 (–0.067, 0.177)
Free oestradiol [pmol/L] 5.026 (0.760, 9.292)* 12.151 (3.353, 20.950)* 6.305 (1.140, 11.470)*
Bioavailable oestradiol [pmo/L] 0.169 (0.007, 0.331)* 0,423 (0.089, 0.757) * 0.214 (0.018, 0.411)*
SHBG [nmol/L] –0.470 (–8.451, –0.096)* –0,950 (–1.734,–0.166)* –0.550 (–1.00,–0.095)*
DHEAS [mg/dL] 0.353 (–1.132, 1.840) 1.051 (–2.047, 4.150) 0.327 (–1.478, 2.132)
LH [IU/L] –0.604 (–2.871, 1.662) –0,445 (–5.185, 4.295) –0,617 (–3.370, 2.135)
FSH (IU/L) –0.963 (–2.844, 0.916) –2.380 (–6.295, 1.535) –1.287 (–3.562, 0.998)
*p<0.05 
Table IV. Association between sex hormones or SHBG and QUS parameters in younger (18–30 years) and older (31–39 years) men
Tabela IV. Relacje pomiędzy stężeniami hormonów lub SHBG a parametrami QUS u młodszych (16–30 lat) i starszych (31–39 
lat) badanych
BUA (dB/Mhz) 
β-coefficient (95% CI)
SOS (m/s) 
β-coefficient (95% CI)
QUI 
β-coefficient (95% CI)
Testosterone [nmol/L]
Younger
Older
0.398 (–1.816, 1.617) 
–0.183 (–1.303, 0.936)
1.989 (–0.646, 4.624)
–0.360 (–2.360, 1.720)
0.911 (–0.612, 2.435)
–0.216 (–1.143, 1.088)
Free testosterone [pmol/L]
Younger
Older
0.050 (0.009, 0.091)* 
0.004 (–0.046, 0.054)
0,145 (0.058, 0.232)*
0,001 (–0.095, 0.091)
0.075 (0.024, 0.126)* 
0.001 (0.055, 0.057)
Bioavailable testosterone [nmol/L] 
Younger
Older
1.602 (–0.009, 3.195)*
0.233 (–1.812, 0.817)
4.875 (1.490, 8.259)*
0.101 (–3.704, 3.907)
2.483 (0.505, 4.461)* 
0.142 (–2.157, 2.443)
Oestradiol [pmol/L]
Younger
Older
0.027 (–0.103, 0.158)
 0.045 (–0.137, 0.229)
0.150 (–0.136, 0.438)
 –0.002 (–0.345, 0.339)
0.056 (–0.109, 0.222) 
0.018 (–0.188, 0.225)
Free oestradiol [pmol/L]
Younger
Older
5.614 (0.302, 11.199)* 
3.940 (–3.967, 11.847)
15.991 (3.991, 27.992)*
3.393 (–11.494, 18.282)
7.813 (0.786, 14.840)*
3.015 (–5.948, 11.979)
Bioavailable oestradiol [pmo/L]
Younger
Older
0.172 (–0.004, 0.386) 
0.160 (–0.145, 0.465)
0.531 (0.070, 0.991)* 
0,138 (–0.436, 0.713) 
0.248 (–0.020, 0.517) 
0.122 (–0.223, 0.468)
SHBG [nmol/L] 
Younger
Older
–0.890 (–1.487, –0.294)*
 –0.206 (–0.728, 0.315)
–1.824 (–3.164, –0.483)*
 –0.325 (–1.298, 0.647)
–1.049 (–1.817, –0.281)*
 –0.215 (–0.802, 0.371)
*p < 0.05
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18 and 26 years of age, before the BMI becomes stable 
in later ages (A). Free (B) and bio-available E2 (C) levels 
declined beginning at the 30–32 year range and reach-
ing their lowest points in the 36–39 age range. In turn, 
SHBG level increased in the 26–29 age range and in the 
36–39 age range (Fig. 2). 
Discussion
The immunoassay (IA) methods for gonadal sex hor-
mone determination used herein have their limitations 
as to accuracy and precision, and switching to more 
specific mass spectrometry (MS) — based methods 
has been advocated. However, it has been recently 
shown that serum T levels show a high correlation over 
a broad concentration range when measured by IA and 
MS, indicating that IA is acceptable for T determination 
[15]. Although the IA/MS correlation was weaker in 
measuring E2 at lower concentrations, the correlation 
between IA and MS was high (R = 0.74, P < 0.001) at 
E2 concentrations higher than 40.8 pmol/L, and the IA 
sensitivity was shown to be 88.4% and specificity 88.6% 
at E2 concentrations above 120 pmol/L [15]. The levels 
of total E2 reported here ranged between 45.5 and 208.8 
pmol/L, indicating the reliability of IA determinations. 
When comparing the clinical applicability of E2 data 
in studies that included bone mass density, Kholsa 
et al. [16] and Ohlsson et al. [17] have concluded that 
although the MS data provides more accurate meas-
urements, the use of IA for E2 determination in bone 
analysis is still valid. 
We have shown that the levels of free and bio-
available fractions of both T and E2, but not other 
examined hormones, were positively associated with 
QUS parameters. Age influenced this issue because 
after dichotomisation for age, the associations re-
Table V. Means (SD) of hormone levels, SHBG and QUS 
parameters in younger (18–30 years, n = 47) and older (31–39 
years, n = 33) age groups. Comparisons with ANOVA or 
Mann-Whitney test
Tabela V. Średnie (SD) stężenia hormonów, SHBG 
i parametrów QUS u młodszych (18–30 lat, n = 47) i starszych 
(31–39 lat, n = 33) badanych. Porównania z zastosowaniem 
testu ANOVA lub testu Manna-Whitneya
Variable 18–30 yrs 31–39 yrs P value
Total T [nmol/L] 18.1 (4.5) 18.5 (6.1) 0.922
Free T [pmol/L] 429.0 (125.2) 415.0 (137.3) 0.463
Bio T [nmol/L] 11.1 (3.3) 10.4 (3.4) 0.218
Total E2 [pmol/L] 122.2 (41.8) 101.3 (37.4) 0.031
Free E2 [pmol/L] 2.7 (0.9) 2.2 (0.9) 0.008
Bio E2 [pmol/L] 70.2 (25.3) 54.4 (22.2) 0.006
SHBG [nmol/L] 24.1 (8.4) 28.0 (13.1) 0.256
DHEAS [µmol/L] 7.8 (2.9) 6.6 (2.6) 0.053
LH [IU/L] 4.6 (1.8) 4.5 (1.9) 0.660
FSH [IU/L] 4.1 (2.3) 4.1 (2.1) 0.860
BMI [kg/m2] 24.6 (3.9) 26.1 (3.2) 0.034
SOS [m/s] 1565.6 (40.5) 1554.6 (34.9) 0.215
BUA [dB/MHz] 89.8 (18.3) 86.9 (18.8) 0.256
QUI 106.9 (23.2)  102.0 (21.1) 0.358
Bio — bioavailable
Figure 1. Changes in body mass index (BMI) (A), serum level of 
free oestradiol (B) and bioavailable oestradiol (C) (mean ± SD) 
with dependence of age. P — one-way ANOVA test. Number of 
participants per age interval in parenthesis
Rycina 1. Zmiany wskaźnika masy ciała (BMI) (A), stężenia 
wolnego estradiolu w surowicy (B) i stężenia estradiolu 
biodostępnego (C) (średnia ± SD) w zależności od wieku. 
P — reprezentuje test ANOVA. W nawiasach podano liczbę 
badanych w poszczególnych przedziałach wiekowych
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mained significant only in individuals younger than 
30 years. Differences in the number of cases recruited 
as either younger or older than 30 years (n = 47 in 
18–30 years, and n = 33 in 31–39 years) might influ-
ence the findings, but it is more probable that during 
the third decade of life, which reportedly surrounds 
peak bone mass attainment [9–12], bones present 
stronger sensitivity to sex steroids than after the 
30s and hence express significant associations with 
circulating biologically-active T and E2.
In contrast to other studies, we were not able to 
demonstrate a decline in total [18], free [13] or bio-
available [19] T levels in young men with depend-
ence on an age. This discrepancy may arise from the 
different numbers of men examined (more numer-
ous in our study) and differently selected age-spans 
[13, 18]. A new finding in our study is a decline in 
serum level of total E2 in the fourth decade of life. 
A decreased level of total E2 was followed by low-
ered blood concentrations of free and bioavailable 
fractions of E2. A decrease in aromatase activity, an 
enzyme converting T into E2, might be responsible. 
Scarce clinical material available in the literature has 
indicated that although aromatase activity in men 
does not correlate with age, the highest levels of aro-
matase in the blood are observed in men aged 18–20 
years [20]. An age-dependent decrease in total and 
bioavailable E2 levels between young (22–39 years), 
middle-aged (40–59 years) and elderly (60–90 years) 
men has been described previously and attributed 
to the increased serum SHBG levels [21]. Our data 
suggests that these changes may initiate earlier, as 
soon as the 30th year of life. A decrease of total and 
free E2 levels in ageing men was described recently 
in the age span 55–90 years [22]. 
All fractions of E2 may play a crucial role in the 
maintenance of bone health in men, more important 
than T. In middle-aged and elderly men, total and 
free E2, but not T, blood levels positively correlated 
with bone health [4]. Aromatase deficiency (a rare 
autosomal recessive disorder) in young men, despite 
normal or elevated T levels, results in osteopenia and 
osteoporosis [5–8]. Our findings may suggest that age 
or age-related change in blood level of E2 influences 
the association between sex steroid levels and bone 
status in young men. E2 may facilitate the effect of 
T in bones. It cannot be excluded that a specific E2 
threshold may exist in young men to facilitate the 
promotion of bone health by sex steroids. It has been 
suggested than age-related decreases in bioavailable 
E2 levels to less than 40 pmol/L may be the major 
cause of bone loss in elderly men [21]. 
The disappearance of the associations between sex 
hormones and bone quality in men older than 30 years 
observed herein may be transient or relative. It has 
been demonstrated that in men older than 40 years, 
T and E2 may act in concert to improve bone status. 
Dual-energy x-ray absorbtiometry (DEXA) of the radius 
revealed that while bioavailable E2 was responsible for 
the maintenance of cortical and trabecular bone mass 
density (BMD), bioavailable T affected bone health 
through associations with muscle mass and bone area 
in men [23]. 
The fact that SHBG binds, but also inactivates, sex 
steroids is a determinant of the bioavailability for tis-
sue action. In accordance with most [24–27] but not 
all earlier observations [28, 29], circulating SHBG was 
found to negatively correlate with bone parameters. 
After adjustment for other co-variants, SHBG retained 
its negative association with bone status only in the 
younger subgroup. This suggests that SHBG has 
a special importance in the regulation of bones in men 
under 30. The increase of SHBG level between 18 and 
29 years of age and in the oldest age range (36–39 
years) may be in accordance with previous reports [30, 
31]. Although experimental studies have shown that 
SHBG limits access of T to some target tissues such as 
brain, salivary gland, lymph node and prostate, some 
clinical data on BMD investigation renders against free 
hormone hypothesis. Namely, in some studies, higher 
levels of SHBG have been shown to be associated with 
higher BMD in men. Accordingly, SHBG may not only 
be an inhibitor, but also a facilitator (or both) of sex 
steroid action [32].
Figure 2. Changes in serum level of sex hormone binding globulin 
(SHBG) with dependence of age (median, 25th and 75th percentile 
and minimum and maximum). P – Kruskal-Wallis test. Number 
of participants per age interval in parenthesis
Rycina 2. Zmiany stężenia białka wiążącego steroidy płciowe 
(SHBG) w surowicy w zależności od wieku (mediana, wartości 
25. i 75. percentyli oraz wartości najniższej i janwyższej). P — 
reprezentuje test Kruskal’a-Wallis’a. W nawiasach podano liczbę 
badanych w poszczególnych przedziałach wiekowych
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LH and FSH levels did not relate to QUS parameters, 
suggesting that SHBG and albumins, but not supra-
testicular stimulating hormones, play a primary role 
in regulating the availability of sex steroid in bones. 
No association between adrenal sex steroid DHEAS 
and QUS parameters was present, but it has been 
shown that DHEAS is active mostly in men of less 
than 20 years of age. Indirect evidence exists that an 
association between DHEAS and bone accrual would 
be better demonstrated in young women rather than 
men. Namely, the strength of the negative correlation 
between DHEAS level and bone turnover is higher in 
young females than in males [18].
The limitation of this study is the low number of 
cases investigated. The overall response rate for partici-
pation was 26.7%. This might be because young men 
were invited. In the European Male Ageing Study, ex-
ploring the relationship between gonadal steroid status 
and bone health in the older population, the response 
rate was 45% [4, 33]. Any factors influencing partici-
pation, however, are unlikely to have influenced the 
association between hormones and QUS parameters, 
which are based on an internal comparison of those 
who participated. 
The main strength of our study is that it is based on 
the use of standardised methods to assess bone health 
and that hormone measurements were performed in 
one run to minimise assay variability. Our results are 
based on assessment of the calcaneus, a trabecular bone 
which may be more sensitive to sex hormone levels than 
cortical bone. The results may therefore be difficult to 
extrapolate to other skeletal sites. Unlike DEXA, there 
are no published methods for cross calibration between 
QUS scanners, but the results reported are the data 
obtained at one centre. In ageing men, QUS measure-
ments predict the risk of any non-spine fracture almost 
as well as hip DEXA measurements [9]. 
In summary, free and bioavailable fraction levels of 
T and E2 in the circulation are associated positively, and 
SHBG level negatively, with the bone status of men until 
the end of their third decade of life and until the blood 
level of E2 begins to decline. The influence of gonadal 
steroids on bones in young adult men may depend on 
age and blood level of E2.
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